

## References Human Proteases Research (Products: MMPs, HtrAs, Aggrecan, Collagens, Zymography Service)

### MMPs:

“Biochemical characterization of the catalytic domain of membrane-type 4 matrix metalloproteinase”. Kolkenbrock H, Essers L, Ulbrich N, **Will H. Biol Chem.** 1999 Sep;380(9):1103-8.

“Localization of the human membrane-type 2 matrix metalloproteinase gene (MMP15) to 16q12.1 near DNA elements that are part of centromeric and non-centromeric heterochromatin of 11 human chromosomes”. Koehler MR, Sauer CG, Reismann N, Steinlein C, Weber BH, **Will H, Schmid M. Chromosome Res.** 1998 Apr;6(3):199-203.

“Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases”. d'Ortho MP, **Will H, Atkinson S, Butler G, Messent A, Gavrilovic J, Smith B, Timpl R, Zardi L, Murphy G. Eur J Biochem.** 1997 Dec 15;250(3):751-7.

“The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study”. Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, Schade van Westrum S, Crabbe T, Clements J, d'Ortho MP, Murphy G. **J Biol Chem.** 1998 Jan 9;273(2):871-80.

“Activation of progelatinase A and progelatinase A/TIMP-2 complex by membrane type 2-matrix metalloproteinase”. Kolkenbrock H, Hecker-Kia A, Orgel D, Ulbrich N, **Will H. Biol Chem.** 1997 Feb;378(2):71-6.

“The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3”. **Will H, Atkinson SJ, Butler GS, Smith B, Murphy G. J Biol Chem.** 1996 Jul 19;271(29):17119-23.

“Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme”. Knäuper V, **Will H, López-Otin C, Smith B, Atkinson SJ, Stanton H, Hembry RM, Murphy G. J Biol Chem.** 1996 Jul 19;271(29):17124-31.

### HtrAs:

“Alpha-1-antitrypsin: a novel human high temperature requirement protease A1 (HTRA1) substrate in human placental tissue”. Frochaux V, Hildebrand D, **Talke A, Linscheid MW, Schlüter H., PLoS One.** 2014 Oct 20;9(10):e109483. doi: 10.1371/journal.pone.0109483. eCollection 2014.

"HtrA3 as an Early Marker for Preeclampsia: Specific Monoclonal Antibodies and Sensitive High-Throughput Assays for Serum Screening". Dynon K, Heng S, Puryer M, Li Y, Walton K, **PLoS ONE,** 2012; 7(9): e45956. doi:10.1371/journal.pone.0045956

“Human HtrA4 Expression Is Restricted to the Placenta, Is Significantly Up-Regulated in Early-Onset Preeclampsia, and High Levels of HtrA4 Cause Endothelial Dysfunction”. Singh H1, Zhao M1, Chen Q1, Wang Y1, Li Y1, Kaitu'u-Lino TJ1, Tong S1, Nie G1. **J Clin Endocrinol Metab.** 2015 Jul;100(7):E936-45. doi: 10.1210/jc.2014-3969. Epub 2015 May 6.

### Aggrecanase Activity Assay:

“A quantitative assay for aggrecanase activity”. **Will H, Dettloff M, Bendzkô P, Sveshnikov P. J Biomol Tech.** 2005 Dec;16(4):459-72.

### Aggrecan:

“Truncation of the amino-terminus of the recombinant aggrecan rAgg1mut leads to reduced cleavage at the aggrecanase site. Efficient aggrecanase catabolism may depend on multiple substrate interactions”. Hörber C, Büttner FH, Kern C, Schmiedeknecht G, Bartnik E. **Matrix Biol.** 2000 Nov;19(6):533-43.

#### **Collagens:**

"A matrilin-3 mutation associated with osteoarthritis does not affect collagen affinity but promotes the formation of wider cartilage collagen fibrils". Otten C, Hansen U, **Talke A**, Wagener R, Paulsson M, Zaucke F. **Hum Mutat.** 2010; 31(3):254-63. doi: 10.1002/humu.21182.

“Proteolytic processing causes extensive heterogeneity of tissue matrilin forms”. Ehlen HW, Sengle G, Klatt AR, **Talke A**, Müller S, Paulsson M, Wagener R. **J Biol Chem.** 2009 Aug 7;284(32):21545-56. doi: 10.1074/jbc.M109.016568. Epub 2009 Jun 16.

#### **Zymography Service:**

“Proteome analysis identified the PPAR $\gamma$  ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction”. Paulitschke V, Gruber S, Hofstätter E, Haudek-Prinz V, Klepeisz P, Schicher N, Jonak C, Petzelbauer P, Pehamberger H, Gerner C, Kunstfeld R., **PLoS One** 2012;7(9):e46103. doi: 10.1371/journal.pone.0046103. Epub 2012 Sep 25.